Earlier commencement of CFTR modulators is likely to yield benefits in morbidity and mortality, which are closely linked to reduced acute lung disease exacerbation rates and much fewer episodes of lung function decline throughout a CF patient’s life journey [121]. The gene discussed is CFTR; the disease is cystic fibrosis.